ResMed (RMD) Is Down 5.1% After Market Value Slides Despite Solid Fundamentals Has The Bull Case Changed?

Simply Wall St.03:09

In the past week, ResMed’s share price weakness has erased about US$3.30 billion from its market value, leaving the company at roughly US$34.00 billion despite reports that its operating performance ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620275561?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-03-20 03:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620275561","market":"nz","top_or_hot":-1,"title":"ResMed (RMD) Is Down 5.1% After Market Value Slides Despite Solid Fundamentals Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>In the past week, ResMed’s share price weakness has erased about US$3.30 billion from its market value, leaving the company at roughly US$34.00 billion despite reports that its operating performance ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-down-51-after-market-value-slides-despite-soli\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed (RMD) Is Down 5.1% After Market Value Slides Despite Solid Fundamentals Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed (RMD) Is Down 5.1% After Market Value Slides Despite Solid Fundamentals Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 03:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-down-51-after-market-value-slides-despite-soli><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the past week, ResMed’s share price weakness has erased about US$3.30 billion from its market value, leaving the company at roughly US$34.00 billion despite reports that its operating performance ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-down-51-after-market-value-slides-despite-soli\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-down-51-after-market-value-slides-despite-soli","article_id":"2620275561","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-down-51-after-market-value-slides-despite-soli","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620275561","pubTimestamp":1773947367,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In the past week, ResMed’s share price weakness has erased about US$3.30 billion from its market value, leaving the company at roughly US$34.00 billion despite reports that its operating performance and financial condition remain solid.\nThis disconnect between market sentiment and underlying business health raises questions about whether recent trading reflects short-term emotion rather than changes in ResMed’s long-term outlook.\nAgainst this backdrop of recent market value erosion despite...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","AI":"C3.ai, Inc.","BK4587":"ChatGPT概念","BK4528":"SaaS概念","RMD.AU":"Resmed DRC","BK4082":"医疗保健设备","BK4504":"桥水持仓","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4588":"碎股","BK4548":"巴美列捷福持仓","RMD":"瑞思迈","BK7501":"新冠治疗股","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4551":"寇图资本持仓","BK4023":"应用软件","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4543":"AI"},"translate_title":"尽管基本面稳健，瑞思迈(RMD)市值下滑，但仍下跌5.1%牛市情况发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.63,"RMD":0.9,"RMD.AU":1.5,"AIYY":0.6},"content_text":"In the past week, ResMed’s share price weakness has erased about US$3.30 billion from its market value, leaving the company at roughly US$34.00 billion despite reports that its operating performance and financial condition remain solid. This disconnect between market sentiment and underlying business health raises questions about whether recent trading reflects short-term emotion rather than changes in ResMed’s long-term outlook. Against this backdrop of recent market value erosion despite stable fundamentals, we’ll assess how this shift feeds into ResMed’s investment narrative. Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementResMed Investment Narrative RecapTo own ResMed, you need to believe in sustained demand for sleep and respiratory care, supported by its medical device and digital health ecosystem. The recent US$3.30 billion value drop appears sentiment driven rather than a material change to near term catalysts like product innovation, while key risks such as reimbursement pressure and new therapies competing with CPAP remain front of mind and unchanged. Against that backdrop, the recent Q2 2026 results, with higher sales and earnings year on year, look more aligned with the idea of a business still executing on its growth and efficiency catalysts than with a company whose fundamentals have suddenly deteriorated, which is important context when short term market moves appear disconnected from reported performance. Yet investors should also be aware that reimbursement changes or competitive treatments for sleep apnea could still... Read the full narrative on ResMed (it's free!)ResMed's narrative projects $6.4 billion revenue and $1.9 billion earnings by 2028. This requires 7.8% yearly revenue growth and an earnings increase of about $0.5 billion from $1.4 billion today.Uncover how ResMed's forecasts yield a $296.87 fair value, a 30% upside to its current price.Exploring Other PerspectivesRMD 1-Year Stock Price Chart Members of the Simply Wall St Community have published 7 fair value estimates for ResMed, spanning roughly US$179.72 to US$296.87, showing how far apart individual views can be. Against that range, the recent sell off alongside ongoing earnings growth invites you to weigh both sentiment driven price moves and long term business risks before forming your own view.Explore 7 other fair value estimates on ResMed - why the stock might be worth as much as 30% more than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your ResMed research is our analysis highlighting 5 key rewards that could impact your investment decision.Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.Curious About Other Options?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Find 49 companies with promising cash flow potential yet trading below their fair value.Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620275561","isCrawlerRequest":true}